Skip to main content
LUYAN PHARMA CO.,LTD logo

LUYAN PHARMA CO.,LTD — Investor Relations & Filings

Ticker · 002788 ISIN · CNE1000025W1 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2016-06-07 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002788

About LUYAN PHARMA CO.,LTD

https://www.luyan.com.cn

Luyan Pharma Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive logistics network, providing supply chain management services to healthcare institutions, including hospitals and community clinics. Its product portfolio encompasses a wide range of Western pharmaceuticals, traditional Chinese medicines, and medical equipment. In addition to wholesale distribution, the company maintains a significant presence in the retail pharmacy sector through a chain of drugstores. Luyan Pharma focuses on optimizing healthcare delivery through integrated distribution systems and value-added services, such as third-party logistics and pharmaceutical cold chain management. The organization leverages its regional market leadership to expand its service footprint and enhance the efficiency of the medical supply chain.

Recent filings

Filing Released Lang Actions
公司章程（2016年6月）
Governance Information Classification · 95% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of 鹭燕医药股份有限公司, approved by the company's 2016 3rd Extraordinary General Meeting. It contains detailed provisions on company organization, shareholder rights, board and management structure, share issuance, share transfer, shareholder meetings, and other governance matters. It references the Chinese Company Law and Securities Law, and includes detailed rules on shareholder meetings, board responsibilities, and capital changes. This document is a governance document that sets out the internal rules and structure of the company rather than a financial report, announcement, or other filing type. It is not an Annual Report, Interim Report, Earnings Release, nor a Proxy Statement or Voting Results. It is not a regulatory announcement or legal proceeding update. The content matches the definition of Governance Information (CGR), which details the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary. Therefore, the correct classification is CGR with high confidence.
2016-06-07 Chinese
2015年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2015 annual equity distribution (dividend) plan approved at the 2015 annual general meeting. It details the dividend amount, record date, ex-dividend date, dividend recipients, and payment method. The document is relatively short (2725 characters) and serves as a formal notice of dividend distribution rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or management discussion. Therefore, it fits the category of a Notice of Dividend Amount (DIV).
2016-06-06 Chinese
关于公司子公司注销《药品经营许可证》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the cancellation of pharmaceutical business licenses of two subsidiaries due to regulatory changes in vaccine distribution. It provides background on the regulatory change, details about the subsidiaries, their financials, and the impact of the license cancellation on the company. The document is an official announcement about a regulatory and operational change, not a financial report, audit, or management discussion. It does not contain comprehensive financial statements or detailed financial analysis. The document length is short (1786 characters) and it is primarily an announcement of a business change related to regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-06-05 Chinese
第三届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 16th meeting of the 3rd Board of Directors of 鹭燕（福建）药业股份有限公司. It details the meeting procedures, voting results on various proposals including company name change, changes in investment project locations, anti-fraud management system, and convening a shareholders meeting. It also reports on the board hearing a report from the chairman about asset acquisition by a subsidiary. The document is a board meeting resolution announcement, not a full management report or financial statement. It does not contain financial data or detailed management discussion but focuses on board decisions and disclosures. Therefore, it fits best under Board/Management Information (MANG). The document length is short (2452 characters), and it is not an announcement of a report publication but a substantive board meeting resolution disclosure.
2016-05-22 Chinese
第三届监事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 鹭燕（福建）药业股份有限公司 regarding decisions made in their ninth meeting of the third session. It includes voting results on various company matters such as name change, changes in investment project locations, and anti-fraud management system establishment. The document is a formal announcement of board meeting resolutions and does not contain financial statements, audit opinions, or detailed financial data. It is not an annual report, interim report, or earnings release. It also does not fit categories like M&A, capital updates, or legal proceedings. The content aligns with announcements of board or management decisions, specifically from the supervisory board, which is part of company governance and management information. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing fallback. Confidence is high due to clear meeting resolution content and voting results.
2016-05-22 Chinese
国信证券股份有限公司关于公司变更部分募集资金投资项目实施地点的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Guosen Securities regarding a change in the implementation location of certain fundraising investment projects by Luyan (Fujian) Pharmaceutical Co., Ltd. It references regulatory rules related to fundraising and securities issuance, details the original fundraising, and confirms the reasonableness and compliance of the location change. The document is a formal opinion or verification report by the sponsor institution, not a full financial report or earnings release. It does not contain financial statements or quarterly/yearly results. It is not an announcement of voting results or management changes. It is a regulatory compliance-related verification document concerning fundraising use. Given the content and length (2385 characters), it is not a full report but a regulatory filing related to fundraising project changes. Therefore, the best fitting category is Regulatory Filings (RNS).
2016-05-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.